Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: teriparatide
INDICATION: Osteoporosis
DATE: 06/06/2022
STATUS: Authorized
MORE INFORMATION
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
SUBSCRIBE
